Protagenic Therapeutics receives Nasdaq non-compliance letter

Protagenic Therapeutics (PTIX) has received a notification letter from Nasdaq indicating its non-compliance with the exchange’s listing rules, namely the minimum stockholders' equity requirement and timely filing of periodic reports.

The exchange told the company it no longer meets the required $2.5 million minimum stockholders’ equity based on its latest Form 10-QT. The exchange also said the company is out of compliance for not yet filing its September 30, 2025 Form 10-Q. The company says it is finishing the remaining work and expects to file the delayed report soon.

Under Nasdaq Listing Rule 5815, because the company recently regained compliance and remains subject to a mandatory panel monitoring period, the Nasdaq Listing Qualifications Staff has issued a determination to delist the company's securities.

The company will request a hearing before a Nasdaq panel to present its plan to address both deficiencies.

Source: Press Release